The researchers observed similar overall survival rates in NSCLC patients with KRAS G12C and KRAS G12V mutations (11 vs. 10 months, HR 1.0, 95% CI 0.86–1.20, p = 0.88) and KRAS G12D mutations (11 vs. 12 months, HR 0.91, 95% CI 0.75–1.11, p = 0.36) [119]. Here, KRAS is linked to non-small cell lung carcinoma.